Literature DB >> 23468448

Percutaneous closure of a patent foramen ovale to prevent paradoxical thromboembolism in a patient with a continuous-flow LVAD.

Carlo R Bartoli1, Kelly C McCants, Emma J Birks, Michael P Flaherty, Mark S Slaughter.   

Abstract

Patent foramen ovale (PFO) may complicate left ventricular assist device (LVAD) therapy. We report a 70-year-old male with a HeartMate II LVAD at increased risk for thromboembolic stroke secondary to a PFO with right-to-left shunting and a large mobile thrombus on his right atrial pacing lead. Via percutaneous intervention, a 25 mm Cribiform Amplatzer atrial septal occluder was successfully deployed across the PFO without complications. This is the first reported case of percutaneous PFO closure to prevent paradoxical thromboembolism in a normoxic patient with an LVAD. In addition, arterial desaturation and the sequelae of chronic hypoxemia were prevented. Strategies to diagnose PFO at the time of LVAD implantation and physiological implications of a right-to-left atrial shunt during mechanical unloading of the failing left ventricle are reviewed.

Entities:  

Mesh:

Year:  2013        PMID: 23468448

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  2 in total

Review 1.  Patent foramen ovale in children: Unique pediatric challenges and lessons learned from adult literature.

Authors:  Sunil Saharan; Joseph Vettukattil; Aarti Bhat; Venu Amula; Manish Bansal; Devyani Chowdhury; Umesh Dyamenahalli; Saurabh Kumar Gupta; Bibhuti Das; T K Susheel Kumar; Ashok Muralidaran; Kalyani Trivedi; Sethuraman Swaminathan; Neha Bansal; Unnati Doshi; Arvind Hoskoppal; Seshadri Balaji
Journal:  Ann Pediatr Cardiol       Date:  2022-06-14

Review 2.  The practical role of echocardiography in selection, implantation, and management of patients requiring LVAD therapy.

Authors:  Maria Chiara Todaro; Bijoy K Khandheria; Timothy E Paterick; Matt M Umland; Vinay Thohan
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.